CPhI Japan, organised by UBM EMEA and UBM Japan, will be returning to the Tokyo Big Sight Centre for its 16th edition from the April 19-21, 2017. Gathering over 19,600 attendees and 550 exhibitors from 30 countries, the show will co-locate with ICSE, P-MEC, BioPh, and InnoPack. An ageing population, a growing generics market and liberalization of Over-The-Counter medicines make Japan an attractive destination for investments, particularly as the pharma industry undergoes legislative change, with the Government¹s bid to cut healthcare expenditure.
Central to the internationalisation of the Japanese market is CPhI Japan, which returns as the most comprehensive pharma event in the region to provide the latest trends, insights and innovations in the industry. The five-in-one event allows visitors to gain access to the entire Japanese pharma industry under one roof, and meet with exhibitors working across ingredients, contract services, biopharmaceuticals, machinery, technology, and packaging.
Japan is the world's third largest pharma industry, with a market that is forecasted to reach a total value of US$ 115 billion by 2024. However, due to an ageing population and growing healthcare costs, the Government recently committed to increase market penetration of generics from 30 per cent in 2014, to 60 per cent by the end of this year. The surge in demand will open up new opportunities for international pharmaceutical manufacturers, as domestic producers alone will struggle to meet required capacity. High quality Indian generic manufacturers and branded generics, particularly those from the United States and Europe, are well placed to expand market share.
To help explore the market's potential, running alongside the exhibition is a three-day, in-depth conference. CPhI Japan's high-value conference programme enables attendees to learn about the latest trends and strategies in the market. It features bespoke content discussions and special seminars across topics such as An Evolving Pharma Market - Challenges and Opportunities Ahead - Outlook to 2021, and Digital health: What does it mean exactly?.
Additionally, keynote sessions will address current situations and challenges of policy on health insurance and current topics regarding regulation of pharmaceuticals in Japan. Finally, an important session, dedicated to the new pricing and reimbursement system of medicines set in December 2016, will discuss the effects this will have in the market, including the potential reduction in overall prices and increased competition.
Other notable features at CPhI Japan 2017 include: The Customer Insights Lounge enables attendees to interact with CPhI Japan personnel and gather insights about the pharmaceutical market, company developments, and share event experiences.
The renowned Business Matchmaking Programme, an online matchmaking tool, enables attendees to search for and arrange meetings with exhibitors prior to the show.
Exhibitor Showcases will run on the show floor and allow exhibitors 30-minutes to present their products, services, new launches, and innovations to visitors and press.
For more information about CPhI Japan,visit http://www.cphi.com/japan